• Bath & Body Works reported past second-quarter 2026 results with sales of US$1,514 million, higher net income of US$118 million, and diluted EPS of US$0.58, while also tightening revenue guidance and lifting full-year earnings expectations despite forecasting modest sales declines.
• Alongside the earnings update, the company launched its Reserve Collection home fragrance franchise, extending into higher-priced decor-led formats that highlight its push to integrate fragrance, design and gifting into a more premium, year-round assortment.
• Next, we’ll examine how stronger profitability guidance, despite anticipated sales pressure, reshapes Bath & Body Works’ investment narrative and future growth considerations.

Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Bath & Body Works Investment Narrative Recap

To own Bath & Body Works, you need to believe its core fragrance and body care franchise can stay relevant while the business improves profitability despite pressured sales. The latest quarter fits that trade off: sales slipped year on year, but earnings and EPS rose, and full year EPS guidance was raised even as revenue is still expected to decline. The key near term catalyst is margin execution, while the biggest risk remains weak digital performance and uneven demand from newer, younger customers.

The launch of the Reserve Collection ties directly into that margin story, as it broadens the higher priced, decor led home fragrance assortment and supports a more premium, year round offering. While Q3 guidance calls for softer sales and sharply lower EPS versus last year, the combination of richer product mix and tighter cost control is now central to how the company is trying to balance near term earnings with longer term brand relevance.

Yet against this improving profit picture, investors should not ignore the risk that digital underperformance and softening traffic among younger shoppers could...

Bath & Body Works' narrative projects $7.6 billion revenue and $708.4 million earnings by 2029.

Uncover how Bath & Body Works' forecasts yield a $25.64 fair value, a 36% upside to its current price.

Exploring Other Perspectives

Some of the most bearish analysts were assuming roughly flat revenue near US$7.4 billion and earnings slipping toward US$600 million, so compared with the recent guidance lift and product expansion, their view represents a much more cautious stance that you may want to weigh against your own expectations.

Explore 7 other fair value estimates on Bath & Body Works - why the stock might be worth just $19.00!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Bath & Body Works research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Bath & Body Works research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bath & Body Works' overall financial health at a glance.

Contemplating Other Strategies?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 31 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.